NOVARTIS

□□□□□NEN□□□□□□□□□□□□□

□□□□□NEN□□□□□□□□□□□□□

NEN□□□□□□□□□□□□□

VIP□□□ □WDHA□□□□[1,2□]	• □□□□□□89□100□□ • □□□□□□□□67□100□□ • □□□□44□100□□ • □□□□□14□33□□	□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□
□□□□□□□□□□[1,3□]	• □□□58□100%□ • □□□□□45□96%□ • □□□3□18%□ • □□□□□□□□□□□□□□□□□□□□□ • □□□□□□□□□□□14□41%□	□□□□□□□□□□□□□□□□□□□

NIPHS: non-insulinoma pancreatogenous hypoglycemia syndrome, WDHA: watery diarrhea hypokalemia achlorhydria

1□Ito T, Jensen R. Expert Opin Pharmacother. 2021; 22: 685-693.

2□□□□□□□□□□. □□□. 2014; 111: 2263-2271.

3□Khan MS, et al. World J Gastroenterol. 2020; 26: 4537-4556.□□□□

□□□□

□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□NEN□□□□□□□□□□□□□□□□□□□

□□□□□□□□□	• CT/MRI • US • □□□□□/EUS • SASI test□□□□□□□□ • SRS • ^{68}Ga-DOTATOC PET/CT□□□□□□□
MEN1/VHL	• CT/MRI • EUS/EUS-FNA • SASI test□□□□□□□□ • SRS□□□□□□□□
□□□□□NEN	• CT/MRI • US • EUS/EUS-FNA • SRS
□□□NEN	• □□□□□ • □□□□□□□EUS-FNA
NEN□□□□□□	• CT/MRI • US • FDG-PET/CT • SRS

SASI: selective arterial secretagogue injection, US: ultrasonography, EUS: endoscopic ultrasonography, EUS-FNA: endoscopic ultrasound-guided fine needle aspiration, PET: positron emission tomography

□□□□□□□□□□□□□□□□□□□□□□□□2□□□□□□ □. □□□□□□□□□□□□□□NEN□□□□□□□□□ □2□, □□□□□□□□□□□□□□□JNETS□, □□□□, □□, 2019.□□□□

□□□□

NEN□□NET G1/G2□NEC□MiNEN□□□□□□□□□□□□□□□□□□□